Articles tagged with Cervical Cancer
Researchers at UC Berkeley discovered a synthetic peptide that prevents the genital warts virus from infecting cells. The peptide targets the viral E2 protein, which binds to chromosomal proteins, and blocks its action, potentially stopping the spread of the virus and preventing cancer.
A study by Jane Kim and colleagues suggests that introducing a once-in-a-lifetime screen for cervical cancer can provide opportunities to offer additional health checks, such as depression treatment and anemia screening. The optimal package of health services balances monetary limitations and personnel shortages, maximizing health bene...
A study found that only 40% of US women have ever heard of HPV, and fewer still know about its connection to cervical cancer. The public needs education on HPV and cervical cancer to make informed health care choices, researchers concluded.
A study evaluating extended-field intensity-modulated radiation therapy (IMRT) for cervical cancer found that it resulted in significantly reduced side effects and comparable outcomes to standard radiotherapy. The treatment enabled patients to receive full therapeutic doses with less debilitating side effects.
The European Union should make vaccination against the human papillomavirus (HPV) mandatory for all girls aged 11-12 years to prevent cervical cancer. The vaccine offers protection against HPV types 16 and 18, responsible for 70% of all cervical cancers.
A landmark publication from 100 authors offers comprehensive guidance on HPV vaccine administration and cervical cancer screening. The monograph addresses the challenges of expanding HPV-based screening to new populations and recommends universal vaccination strategies for both genders.
Researchers at the University of Manchester have developed a topical treatment against human papilloma virus (HPV) that could potentially prevent cervical cancer. The treatment uses a protease inhibitor already licensed for oral administration, which can selectively kill HPV-infected cells when applied directly to the cervix.
Researchers have discovered a potent inhibitor of HPV infection in the compound carrageenan, found in sexual lubricants and baby food. The study suggests that carrageenan could be effective in preventing HPV-related genital disease, complementing existing vaccines and treatments.
Researchers suggest administering vaccine to young girls starting at age 11-12 for optimal reduction of cervical cancer cases. The new vaccines target types of HPV known to cause cervical and other cancers.
A new strategy detects high-grade precancerous lesions more effectively than traditional smear tests, while minimizing incorrect diagnoses. This approach enables early treatment and improves cure rates for young women aged 25-34 years.
A randomized controlled trial found that HPV testing combined with liquid-based cytology increased sensitivity by 47% compared to conventional pap smears, but also led to a 60% increase in false positives. HPV testing alone showed a 40% increase in sensitivity and a smaller decrease in specificity.
A vaccine against cervical cancer has shown sustained high levels of antibodies for up to 4.5 years, providing substantial long-term protection against cancerous cell changes associated with high-risk HPV types. The vaccine was also found to be effective against persistent and new infections, setting the stage for its widescale adoption.
A study analyzing patient data from over 60,000 women across six countries reveals HPV testing is highly sensitive and reproducible, with a sensitivity rate of 96% overall. Cytology was less effective but more specific in older women.
The HPV vaccine has the potential to prevent cervical cancer, but understanding its context is vital. Vaccination should not be misconstrued as a green light for permissive behavior, but rather as a means of preventing infection in young women.
PET scans can accurately predict prognosis and five-year survival rates in cervical cancer patients. Tumors with high glucose uptake have lower survival rates and disease-free survival rates.
Researchers found a higher frequency of genus beta type HPV antibodies in patients with squamous cell carcinoma (SCC) than control subjects, especially HPV 5. No association was found between HPV and basal cell carcinomas.
A recent study found that HPV infection is a top risk factor for cervical adenocarcinoma globally. The research, conducted on eight case-control studies across Africa, South America, and Southeast Asia, revealed an 80-fold increased risk of cervical adenocarcinoma among HPV-positive women.
Researchers have identified small molecules called indoxins that can potentiate the effectiveness of doxorubicin in E6-expressing colon cancer cells. The compounds drive two distinct cell cycle-related mechanisms, overcoming E6-induced drug resistance and increasing sensitivity to chemotherapy.
Researchers found that living in communities with high poverty rates and certain states significantly predict cervical cancer screening failures among black women. The study suggests community outreach programs should target high-poverty neighborhoods to improve screening rates.
A study by David L. Rimm and colleagues found that high biomarker antibody concentrations were associated with low patient survival in breast cancer patients, while low concentrations were linked to good outcomes. Another study examined the impact of long-term storage on circulating DNA levels in lung cancer patients.
Researchers found a higher rate of pelvic fractures in women who received pelvic irradiation for cancer compared to those who did not. The study, which included 6,428 women aged 65 years and older, showed a significant increase in fracture risk for all three types of cancer diagnoses.
Researchers found that women who underwent radiation therapy for anal and rectal cancer had nearly double the rate of fractures compared to those without radiation therapy. The study also found that most fractures (90%) were hip fractures, highlighting the need for preventive measures.
PET imaging with FDG is a powerful tool in determining the extent of spread of reproductive system cancers, particularly when other conventional tests are ambiguous. Studies have shown its high sensitivity in detecting nodal disease in cervical cancer and its superior detection abilities compared to CT or MRI in recurrent ovarian cancer.
Research from ECCO 13 emphasizes the importance of cervical cancer detection, treatment, and prevention. The study found that adequate radiotherapy significantly improves survival rates for women with cervical cancer, particularly in sub-Saharan Africa where HIV co-infection does not impact survival. The data also highlights the need f...
A single-visit program for cervical cancer screening improved follow-up rates by 53% compared to traditional care, with high-grade lesions also showing increased adherence. The program reduced overall visit time while maintaining patient acceptability, offering a promising solution for underserved communities.
Two 'screen and treat' cervical cancer prevention programs in low-resource settings resulted in lower precancerous lesions and cervical cancer prevalence. Novel non-cytology-based screening methods, such as HPV DNA testing and visual inspection with acetic acid, were associated with significant reductions in cervical cancer risk.
Researchers developed two screen-and-treat methods, HPV DNA testing and visual inspection with acetic acid (VIA), which reduced the prevalence of cervical cancer precursor lesions by 77% compared to traditional cytology-based screening. Cryotherapy was found to be highly efficacious and low-cost.
The GARDASIL vaccine has been shown to be highly effective in preventing high-grade pre-cancerous illnesses and non-invasive cervical cancers. In a larger population analysis, the vaccine prevented 99% of HPV 16 or 18-related high-grade cervical pre-cancers.
The study found that cervical cancer has a significant impact on relationships, intimacy, and instrumental life domains for both women and their partners. Women reported greater illness-induced disruptions to relationships and more fatigue than their partners, highlighting the need for comprehensive psychosocial support.
A phase III study found that GARDASIL vaccine prevented 100% of high-grade cervical pre-cancers and non-invasive cancer cases in women infected with HPV types 16 and 18. The vaccine reduced the risk of developing these cancers by 97%, significantly reducing cervical cancer-related deaths worldwide.
Researchers are working on a next-generation HPV vaccine that is both protective and therapeutic, which can be converted into powder for easier transport. The new vaccine aims to be less expensive than existing options like Cervarix and has shown promise in preventing HPV infection.
Researchers identify HPV types 16 and 18 as key factors in cervical precancer development, supporting targeted management for high-risk women. Night-shift work linked to increased breast cancer risk, while melatonin levels found to lower risk.
Researchers have found that women carrying a certain immune system gene and not having HPV16 are three times less likely to resolve their precancerous lesions. This discovery could provide better targets for cervical cancer vaccine development and potentially allow women to avoid surgery, according to Johns Hopkins scientists.
Researchers have found that adeno-associated virus type 2 (AAV2) can selectively kill cancer cells while leaving healthy cells intact. The study suggests that AAV2 recognizes abnormal cancer cells and induces apoptosis, making it a promising candidate for an anti-cancer therapy.
A study examines the cost-effectiveness of HPV testing in France, Italy, the Netherlands, and the UK, finding both triage and combination strategies to be more effective than current cytology-based screening programs. The cost-effectiveness ratios range from $9,800 to $75,900 per year of life saved, depending on the screening interval.
A new vaccine targeting HPV types 16 and 18, responsible for 70% of cervical cancers and 90% of genital warts, has shown significant effectiveness in reducing persistent infection and disease. The vaccine was 100% effective against precancerous lesions and genital warts associated with these four HPV types.
Research suggests that individuals with more inhibitory killer cell immunoglobulin-like receptors (KIRs) have a decreased risk of developing cervical cancer. Activation of NK cells is thought to contribute to cancer progression by increasing local inflammation, which has been linked to the development of other types of cancer.
A study found that HIV-positive women with normal cervical cytology and negative HPV test results had a similar low cumulative incidence of abnormal lesions compared to HIV-negative women. The authors suggest considering psychosocial costs of positive HPV tests in these women before adjusting screening intervals
A study found that 76% of women would be willing to accept a cervical cancer vaccine for themselves, while 67% of mothers with daughters would consent to have their child vaccinated. The main reasons for non-acceptance were unknown side effects and the belief that minors are not sexually active.
Researchers investigated protein pattern reproducibility, DNA methylation for cervical cancer screening, and tissue zinc concentrations associated with reduced esophageal cancer risk. They found that some methods are not biologically plausible, while others may be useful diagnostic tools.
A $10-million study is recruiting 3,000 healthy men to investigate the transmission of human papillomavirus (HPV), a leading cause of cervical cancer. The research aims to determine whether vaccinating men could help prevent cervical cancer in women.
A new study by Johns Hopkins researchers found a significant association between passive smoking and an increased risk of developing cervical neoplasia. Women who lived with smokers had a 40% or greater risk of developing cervical neoplasia, highlighting the importance of reducing secondhand smoke exposure to prevent cervical cancer.
A recent study by Indiana University School of Medicine found that nearly all sexually active adolescent females aged 14-17 were infected with the human papillomavirus. The researchers also discovered that many of these participants had multiple HPV types, which are associated with an increased risk for cervical cancer.
A study of over 1,500 cervical cancer patients found that older women received less surgery and radiation therapy than younger counterparts. Treatment choices were influenced by tumor stage, medical conditions, and advanced age, which independently affected survival rates.
A vaccine against cervical cancer has been developed by Dutch researcher Laura Bungener. The vaccine induces an immune response to proteins from human papillomavirus (HPV), rendering it harmless and preventing the growth of tumors. Laboratory animals with existing tumors could also be treated with this vaccination.
The study found that 82% of participants tested positive for HPV infection, with many infected with multiple types. High-risk HPV types were detected in 39% of swab specimens, and clinically abnormal cervical exam results were seen in 37% of participants.
A randomized trial has demonstrated that a HPV vaccine is effective in preventing persistent HPV infections, abnormal Pap tests, and precancerous lesions. The vaccine's efficacy rate is up to 95%, suggesting a substantial reduction in cervical cancer rates globally.
A recent study published in The Lancet found that the HPV vaccine is highly effective in preventing cervical cancer, with a 100% success rate among participants who completed the full protocol. The vaccine targets two types of high-risk Human Papillomavirus (HPV-16 and HPV-18) responsible for 70% of cervical cancer cases.
A new HPV vaccine has been shown to be 100% effective in preventing persistent infections that cause cervical cancer. The bivalent vaccine protects against types 16 and 18, the most common causes of cervical cancer, and is also effective at reducing incident or new infections by 91.6 percent.
In a breakthrough procedure, doctors have successfully transplanted a healthy ovary from a patient's body into her upper arm, preserving her fertility. The innovative technique uses brachial vessels to establish blood supply and has shown promising results in maintaining cyclical follicular growth.
A study from Senegal found that urine-based detection of abnormal methylation of three genes provided a sensitivity of 53% and specificity of over 90% for detecting cervical cancer. This approach could have a huge impact on women in developing countries without access to Pap screening.
Yale researchers have been awarded a $7.5 million grant to investigate the role of viruses in cancer development. The grant will support studies on human papillomaviruses, Epstein-Barr Virus, and Kaposi's Sarcoma Herpesvirus, focusing on viral genes and cellular pathways that lead to cancer.
Researchers found that zoledronic acid can halt the progression of cervical cancer in mice by inhibiting angiogenesis and matrix metalloprotease-9 expression. Additionally, a study on skin cancer revealed that Stat3 is required for initiation and promotion stages, suggesting it as a potential target for cancer therapy
Researchers found that zoledronic acid inhibits the growth of cervical cancer by targeting macrophages expressing matrix metalloproteinase-9 (MMP-9) and angiogenesis. This treatment approach offers new hope for cervical cancer patients.
A study found significant socioeconomic disparities in cervical cancer among American women, with higher poverty levels and lower education associated with increased incidence and mortality rates. Women from low-income census tracts were 20% more likely to be diagnosed with late-stage disease than those from high-poverty areas.
A study by Johns Hopkins Bloomberg School of Public Health found that Highly Active Antiretroviral Therapy (HAART) improved the regression rates of cervical squamous intraepithelial lesions (SIL) in HIV-positive women. However, a significant proportion of high-risk lesions persisted even among those who received HAART.
The UK national cervical screening programme has saved approximately 5,000 lives annually by reversing the rising trend in cervical cancer deaths among women under 35. The programme's success has also led to a significant reduction in costs, with a cost per life saved of less than £40,000.
A new HPV vaccine study is underway in women aged 24-45 to prevent cervical cancer and genital warts. The quadrivalent vaccine protects against four common strains of human papillomavirus virus, including two that cause cervical cancer and two that cause genital warts.
A recent study analyzed data from the Behavioral Risk Factor Surveillance System and found that millions of US women who have undergone a hysterectomy are being screened for cervical cancer unnecessarily. The study suggests that factors contributing to continued screenings include lack of awareness, physician enthusiasm for screening, ...
HIV-infected women are 3.9 times more likely to have HPV infection at the outset of the study, and smoking significantly increases this risk. Smoking and HIV infection may each alter the natural history of HPV infection to heighten tumor risk.